Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRT-6160 Phase 1 in Healthy Volunteers
NCT06597799Phase 1Completed
- Sponsor
- Monte Rosa Therapeutics
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MRT-6160 in autoimmune diseases (2 arms), sponsored by Monte Rosa Therapeutics. Primary endpoints: Safety and Tolerability (SAD) at 6 weeks and Safety and Tolerability (MAD) at 7.5 weeks. Started Aug 2024; status: completed.
02
Drugs
MRT-6160
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT06597799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597799.